JP Morgan Asset Management (JPMAM) has partnered with UBS Wealth Management to launch a fund focused on investing in genetic therapies.
The fund, which JPMAM calls an industry first, combines machine learning and active management and uses research from UBS Wealth Management.
The JP Morgan Funds – Thematics – Genetic Therapies will be co-managed by Yazann Romahi, Berkan Sesen and Aijaz Hussein.
According to JPMAM, genetic therapies represent a “once-in-a-generation breakthrough” in the world of medicine.
Genetic therapy treatments offer the hope of a cure for patients with serious inherited diseases by modifying genetic information to address the underlying cause of the disease, the firm said.
Mark Haefele, chief investment officer at UBS Global Wealth Management, said: “Genetic therapies could develop into a profoundly disruptive technology for the pharmaceutical and biotechnology industry.
“Positioning portfolios to capture the economic benefits of disruption, while hedging or mitigating its effects on other assets, supports our goal to help our clients protect and grow their wealth over generations.”
©2019 funds europe
